Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
  • The Children's Hospital of Philadelphia
  • RTI International
  • National Institutes of Health
  • Women and Infants Hospital of Rhode Island
  • University of North Carolina at Chapel Hill
  • Riley Hospital for Children
  • Cincinnati Children's Hospital Medical Center
  • University of Texas Health Science Center at Houston
  • Case Western Reserve University
  • The University of Chicago
  • Columbia University
  • University of Missouri at Kansas City
  • Duke University
  • Emory University
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Ohio State University
  • Stanford University
  • Tufts Medical Center
  • University of Alabama at Birmingham
  • University of California at Los Angeles
  • University of Iowa
  • University of New Mexico
  • University of Pennsylvania
  • University of Rochester
  • University of Texas Southwestern Medical Center
  • University of Utah
  • Hutzel Women's Hospital
  • Yale University

Producción científica › revisión exhaustiva

42 Citas (Scopus)

Resumen

Objective To assess the association between prophylactic indomethacin and bronchopulmonary dysplasia (BPD) in a recent, large cohort of extremely preterm infants. Study design Retrospective cohort study using prospectively collected data for infants with gestational ages < 29 weeks or birth weights of 401-1000 g born between 2008 and 2012 at participating hospitals of the National Institute of Child Health and Human Development Neonatal Research Network. Infants treated with indomethacin in the first 24 hours of life were compared with those who were not. Study outcomes were BPD, defined as use of supplemental oxygen at 36 weeks postmenstrual age among survivors to that time point, death, and the composite of death or BPD. Prespecified subgroup analyses were performed. Results Prophylactic indomethacin use varied by hospital. Treatment of a patent ductus arteriosus after the first day of life was less common among 2587 infants who received prophylactic indomethacin compared with 5244 who did not (21.0% vs 36.1%, P < .001). After adjustment for potential confounders, use of prophylactic indomethacin was not associated with higher or lower odds of BPD (OR 0.89, 95% CI 0.72-1.10), death (OR 0.80, 95% CI 0.64-1.01), or death or BPD (OR 0.87, 95% CI 0.71-1.05). The only evidence of subgroup effects associated with prophylactic indomethacin were lower odds of death among infants with birth weights above the 10th percentile and those who were not treated for a patent ductus arteriosus after the first day of life. Conclusions Prophylactic indomethacin was not associated with either reduced or increased risk for BPD or death. Trial registration ClinicalTrials.gov:

Idioma originalEnglish
Páginas (desde-hasta)34-40.e2
PublicaciónJournal of Pediatrics
Volumen186
DOI
EstadoPublished - jul 2017
Publicado de forma externaSí

Huella

Profundice en los temas de investigación de 'Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants'. En conjunto forman una huella única.

Citar esto